Vanguard Group Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,547,138 shares of the medical equipment provider’s stock after purchasing an additional 1,200,825 shares during the quarter. Vanguard Group Inc. owned approximately 10.53% of Hologic worth $1,340,850,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of HOLX. Mutual of America Capital Management LLC boosted its position in Hologic by 1.3% during the first quarter. Mutual of America Capital Management LLC now owns 34,720 shares of the medical equipment provider’s stock worth $1,477,000 after purchasing an additional 453 shares in the last quarter. Airain ltd purchased a new position in Hologic during the first quarter worth approximately $302,000. Mason Street Advisors LLC boosted its position in Hologic by 1.4% during the first quarter. Mason Street Advisors LLC now owns 38,597 shares of the medical equipment provider’s stock worth $1,642,000 after purchasing an additional 538 shares in the last quarter. Pacer Advisors Inc. boosted its position in Hologic by 4.3% during the first quarter. Pacer Advisors Inc. now owns 8,134 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 337 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in Hologic by 13.1% during the first quarter. Private Advisor Group LLC now owns 12,394 shares of the medical equipment provider’s stock worth $523,000 after purchasing an additional 1,437 shares in the last quarter. Institutional investors own 96.38% of the company’s stock.

HOLX has been the topic of a number of recent analyst reports. Royal Bank Of Canada lowered their price target on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. BidaskClub downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC decreased their target price on Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $48.43.

In related news, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Elaine Ullian sold 8,849 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the sale, the director now directly owns 23,810 shares in the company, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. Insiders have sold a total of 27,594 shares of company stock worth $1,168,871 in the last three months. Corporate insiders own 0.79% of the company’s stock.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at 37.57 on Monday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The firm has a market cap of $10.54 billion, a PE ratio of 13.99 and a beta of 0.92. The company has a 50 day moving average price of $38.51 and a 200 day moving average price of $42.54.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.51 EPS. On average, analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/hologic-inc-holx-holdings-boosted-by-vanguard-group-inc/1586889.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.